Navigation Links
Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
Date:8/24/2009

y that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding retigabine's potential in the treatment of postherpetic neuralgia and the impact of this clinical study on the filing of the New Drug Application. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002
    '/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Valeant Pharmaceuticals Reports Second Quarter Financial Results
2. Valeant to Acquire Tecnofarma, A Mexican Generic Company
3. Valeant Pharmaceuticals to Announce 2009 Second Quarter Results on August 4, 2009
4. Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
5. Valeant Announces Increase to Securities Repurchase Program
6. Valeant to Acquire Polish Dermatology Company
7. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
8. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
9. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
10. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
11. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... of the gastro-intestinal tract has long been considered to ... the Sahlgrenska Academy have used refined microscopic techniques that ... surface of the gastro-intestinal tract is only as large ... , The digestive tract, which passes from the mouth ... a length of about 5 meters in a normal ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... in the popular Swedish children,s TV show Bolibompa, ... A new study from the University of Gothenburg ... programmes as well as the link between young ... , Steingerdur Olafsdottir,s doctoral thesis focuses on the ... TV show Bolibompa. Healthy foods dominated in the ...
(Date:4/23/2014)... from the Cancer Science Institute of Singapore (CSI Singapore) ... cancer specific stem cell which causes gastric cancer. This ... for the treatment of this disease and other types ... Chan Shing Leng, Research Assistant Professor at CSI Singapore, ... of a cell surface protein, CD44v8-10, marks gastric cancer ...
(Date:4/23/2014)... published in the journal Oncotarget , explored ... appearances or their own DNA signatures within the ... to design effective, targeted treatment strategies. , Firstly ... mutation and either the KRAS or BRAF mutation. ... the EGFR gene mutation have that specific mutation ...
Breaking Medicine News(10 mins):Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... Nov. 29 As family members age, they,often become ... such as cooking and laundry. Some need help recovering ... care, and most,want to stay in the familiar surroundings ... keep their parents safe, healthy and cared for without,placing ...
... Two fibro-cartilaginous crescents, the menisci serve as cushions against joint ... thigh bones. Loss of meniscal function is recognized as ... the United States, about 6 percent of the over 30 ... senior citizens, age 65 and up, suffer from knee OA ...
... TARRYTOWN, N.Y., Nov. 28 EpiCept Corporation,(Nasdaq and ... Talley,President and CEO, will present a company overview ... on December 5, 2007 at 11:00 a.m.,Eastern Time. ... Broadway Hotel,in New York City on December 4th ...
... 28 Conseco, Inc. (NYSE:,CNO) said today that it has ... Term Care Group, Inc. (LTCG) for certain,back-office functions of the ... Conseco announced earlier this year that it was,considering this solution. ... responsibility for the customer call center and the ...
... Day Special ... Madonna and exclusive performances from Cyndi Lauper, Indigo ... NEW YORK, Nov. 28 SIRIUS Satellite Radio,(Nasdaq: SIRI ) today ... with an exclusive broadcast event on SIRIUS OutQ,109, the nation,s first and ...
... Grades on Key Benchmarks, WASHINGTON, Nov. 28 ... state-specific Report,Card on Lung Cancer. The Report Card ... by the state of Massachusetts. LCA-MA is a ... is the number one cause of cancer deaths ...
Cached Medicine News:Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 2Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 3Health News:Meniscal damage and the development of persistent knee pain 2Health News:Meniscal damage and the development of persistent knee pain 3Health News:EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 2Health News:EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 4Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 5Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 2Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 3Health News:Lung Cancer Alliance-Massachusetts Issues Inaugural State-Specific Report Card on Lung Cancer 2
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Emeryville, Calif., Aug. 18 Adamas Pharmaceuticals, Inc., ... entered into a Cooperative Research and Development Agreement (CRADA) ... preclinical studies evaluating Adamas, triple combination antiviral drug (TCAD) ... TCAD therapy includes Adamas, investigational proprietary fixed-dose oral combination ...
... Aug. 17 Stereotactic body radiotherapy (SBRT) is a highly effective ... new research from The University of Texas in Houston, according to ... Miami and Palm Beach. , ( www.cyberkni f ... "This data confirms the established method of cancer treatment used ...
Cached Medicine Technology:Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain 2Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain 3New Research Shows Effectiveness of Stereotactic Body Radiotherapy for Spinal Tumors 2
Cushing periosteal elevators, rounded edge, sharp, wide, blade width 5/8" (16 mm), length 7 1/4" (184 mm)....
Barr periosteal elevators....
Molt 9 periosteal elevators....
Miller Collburn periosteal elevators....
Medicine Products: